UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  ------------

                                    FORM 6-K

                                  ------------

                            REPORT OF FOREIGN ISSUER

                       Pursuant to Rule 13a-16 or 15d-16
                     of the Securities Exchange Act of 1934


                                  JULY 6, 2009


                                  ------------

                                NOVO NORDISK A/S
             (Exact name of Registrant as specified in its charter)


                                    NOVO ALLE
                               DK-2880, BAGSVAERD
                                     DENMARK
                    (Address of principal executive offices)

                                  ------------

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

                       Form 20-F [X]     Form 40-F [ ]


Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                             Yes [ ]     No [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________



TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

On 29 January 2009, Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to
DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 29 June 2009, the following transactions have been
made under the programme:

                                    NUMBER OF           AVERAGE      TRANSACTION
                                       SHARES    PURCHASE PRICE       VALUE, DKK
ACCUMULATED, LAST ANNOUNCEMENT      8,384,682                      2,320,979,357
29 June 2009                           75,000          283.8500       21,288,750
30 June 2009                           75,000          287.5500       21,566,250
1 July 2009                            75,000          291.6000       21,870,000
2 July 2009                            75,000          290.4900       21,786,750
3 July 2009                            75,000          289.5900       21,719,250
ACCUMULATED UNDER THE PROGRAMME     8,759,682                      2,429,210,357

With the transactions stated above, Novo Nordisk owns a total of 19,551,741
treasury shares, corresponding to 3.2% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.

Further information:

Media:                       Investors:

Outside North America:       Outside North America:
Rachel Curtis Gravesen       Mads Veggerby Lausten
Tel: (+45) 4442 7603         Tel: (+45) 4443 7919
rcgv@novonordisk.com         mlau@novonordisk.com

                             Kasper Roseeuw Poulsen
                             Tel: 4442 4471
                             krop@novonordisk.com

In North America:            In North America:
Sean Clements                Hans Rommer
Tel: (+1) 609 514 8316       Tel: (+1) 609 919 7937
secl@novonordisk.com         hrmm@novonordisk.com

Company Announcement no 41 / 2009



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf of the
undersigned, thereunto duly authorized.

Date: JULY 6, 2009                          NOVO NORDISK A/S
                             ---------------------------------------------------
                                            Lars Rebien Sorensen,
                                     President and Chief Executive Officer